United States set
language
Menu Shopping cart $0 Search

Human IgG1 Anti SARS-CoV-2 Spike (S1) Antibody, Clone: CR3022

  • Regulatory status:RUO
  • Type:Recombinant Monoclonal Antibody
  • Other names:Severe acute respiratory syndrome coronavirus 2 spike glycoprotein S1, 2019 novel coronavirus S1 protein, SARS-CoV-2 S1 subunit, COVID-19
  • Species:Human
Cat. No. Size Price


New RM812422100 0.1 mg
PubMed Product Details
Technical Data

Type

Recombinant Monoclonal Antibody

Hosts

Human

Isotype

IgG1, kappa

Clone

CR3022

Preparation

This is a recombinant monoclonal antibody. The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.

Amino Acid Sequence

Antibody binds to both SARS-CoV and SARS-CoV-2 (COVID-19) with high affinity at amino acids 318-510 in the S1 domain of the Spike protein.

Species Reactivity

SARS-CoV and SARS-CoV-2 (COVID-19)

Purification Method

Affinity chromatography on a column with immobilized protein A.

Antibody Content

0.1 mg; concentration: 1.0 mg/ml For actual concentration see the Certificate of Analysis.

Formulation

Supplied as a liquid in PBS, 0.02% Proclin 300.

Applications

ELISA, Crystallography, NTRL

Antibodies Applications

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Short Term Storage: Up to 3 months at +4ºC Long Term Storage: -20ºC

Note

Products are for Research Use or for Further Manufacturing Use only. Not for Diagnostic or Therapeutic Use.

Summary

Research topic

Immune Response, Infection and Inflammation, COVID-19

Summary

Coronaviruses (CoVs), within the order Nidovirales, are enveloped, single-strand, positive-sense RNA viruses with a large genome of approximately 30 kbp in length. A human infecting coronavirus (viral pneumonia) initially known as 2019 novel coronavirus (2019-nCoV) was found in the fish market at the city of Wuhan, Hubei province of China in December 2019. The virus is now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
SARS-CoV-2 shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. SARS-CoV-2 has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the SARS-CoV-2 might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans.

While bats are possibly the host of SARS-CoV-2, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the SARS-CoV-2 is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus.

Coronaviruses contain at least four structural proteins: Spike (S) protein, envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein.
The spike (S) glycoprotein is a type I transmembrane glycoprotein that plays an important role in mediating viral infection and is common to all HCoVs. The S proteins consist of two subunits, S1 and S2. The S1 subunit binds the cellular receptor through its receptor-binding domain (RBD), followed by conformational changes in the S2 subunit, which allows the fusion peptide to insert into the host target cell membrane. The heptad repeat 1 (HR1) region in the S2 subunit forms a homotrimeric assembly, which exposes three highly conserved hydrophobic grooves on the surface that bind heptad repeat 2 (HR2). This six-helix bundle (6-HB) core structure is formed during the fusion process and helps bring the viral and cellular membranes into close proximity for viral fusion and entry. Thus, the S protein is an important target protein for the development of specific drugs.

Related Products Docs
Subscribe to Our Newsletter! Discover News from
BioVendor R&D
Subscribe Now
Subscribe to Our Newsletter! Discover News from
BioVendor R&D
Subscribe Now
zavřít